

Commercial/Healthcare Exchange PA Criteria Effective: September 14, 2021

Prior Authorization: Accrufer

Products Affected: Accrufer (ferric maltol) oral capsules

<u>Medication Description</u>: Ferric maltol delivers iron for uptake across the intestinal wall and transfer to transferrin and ferritin; it dissociates upon uptake from the gastrointestinal tract allowing iron and maltol to be absorbed separately.

Covered Uses: Iron deficiency

Exclusion Criteria:

- 1. History of hypersensitivity to ferric maltol or any component of the product
- 2. History of hemochromatosis and other iron overload syndromes
- 3. History of receiving repeated blood transfusions

Required Medical Information:

- 1. Diagnosis
- 2. Previous medications tried and failed

Age Restrictions: 18 years of age and older

Prescriber Restrictions: None

Coverage Duration: 6 months for initial and 1 year for continuation of therapy

Other Criteria:

I. Initial Approval Criteria

1. Iron deficiency

Patient must meet all the below criteria:

- A. Diagnosis of Iron deficiency; AND
- B. Trial and failure or intolerance to at least two over-the-counter iron products

II. Continued Therapy

1. Iron deficiency

A. Member has responded positively to the treatment as determined by the prescribing physician, based on improvement in Hb/Ferritin levels; AND

Last Rev. September 2021





B. Member has not experienced unacceptable toxicity from the drug. (e.g- severe GI adverse effects, Iron overload, etc)

References:

- 1. Accrufer [package insert]. Shield Therapeutics Inc. Updated July 13, 2021. Accessed July 29, 2021.
- 2. Accrufer. IBM Micromedex® [database online]. Greenwood Village, CO. Truven Health Analytics. Available at: https://www.micromedexsolutions.com. Updated July 16, 2021. Accessed July 29, 2021.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	9/14/2021

